nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—Reaction gastrointestinal—Methotrexate—muscle cancer	0.0312	0.0312	CcSEcCtD
Fosamprenavir—Osteonecrosis—Methotrexate—muscle cancer	0.028	0.028	CcSEcCtD
Fosamprenavir—Opportunistic infection—Methotrexate—muscle cancer	0.0259	0.0259	CcSEcCtD
Fosamprenavir—Opportunistic infection—Doxorubicin—muscle cancer	0.0224	0.0224	CcSEcCtD
Fosamprenavir—Drug hypersensitivity—Doxorubicin—muscle cancer	0.0224	0.0224	CcSEcCtD
Fosamprenavir—Myositis—Doxorubicin—muscle cancer	0.0184	0.0184	CcSEcCtD
Fosamprenavir—Inflammation—Etoposide—muscle cancer	0.0179	0.0179	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.0157	0.0157	CcSEcCtD
Fosamprenavir—Neutropenia—Dactinomycin—muscle cancer	0.0141	0.0141	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.014	0.014	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.0133	0.0133	CcSEcCtD
Fosamprenavir—Neutropenia—Vincristine—muscle cancer	0.0126	0.0126	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Doxorubicin—muscle cancer	0.0125	0.0125	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Vincristine—muscle cancer	0.0118	0.0118	CcSEcCtD
Fosamprenavir—Myocardial infarction—Vincristine—muscle cancer	0.0118	0.0118	CcSEcCtD
Fosamprenavir—Erythema multiforme—Dactinomycin—muscle cancer	0.0114	0.0114	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Etoposide—muscle cancer	0.0111	0.0111	CcSEcCtD
Fosamprenavir—Inflammation—Methotrexate—muscle cancer	0.0107	0.0107	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Vincristine—muscle cancer	0.0106	0.0106	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Vincristine—muscle cancer	0.0106	0.0106	CcSEcCtD
Fosamprenavir—Urethral disorder—Vincristine—muscle cancer	0.0106	0.0106	CcSEcCtD
Fosamprenavir—Neutropenia—Etoposide—muscle cancer	0.0102	0.0102	CcSEcCtD
Fosamprenavir—Cardiac disorder—Vincristine—muscle cancer	0.01	0.01	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00964	0.00964	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Etoposide—muscle cancer	0.00959	0.00959	CcSEcCtD
Fosamprenavir—Myocardial infarction—Etoposide—muscle cancer	0.00953	0.00953	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—muscle cancer	0.0093	0.0093	CcSEcCtD
Fosamprenavir—Myalgia—Dactinomycin—muscle cancer	0.00894	0.00894	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Methotrexate—muscle cancer	0.00869	0.00869	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Etoposide—muscle cancer	0.00862	0.00862	CcSEcCtD
Fosamprenavir—Urethral disorder—Etoposide—muscle cancer	0.00856	0.00856	CcSEcCtD
Fosamprenavir—Erythema multiforme—Etoposide—muscle cancer	0.00825	0.00825	CcSEcCtD
Fosamprenavir—Anorexia—Dactinomycin—muscle cancer	0.00817	0.00817	CcSEcCtD
Fosamprenavir—Cardiac disorder—Etoposide—muscle cancer	0.0081	0.0081	CcSEcCtD
Fosamprenavir—Myalgia—Vincristine—muscle cancer	0.00799	0.00799	CcSEcCtD
Fosamprenavir—Immune system disorder—Etoposide—muscle cancer	0.00789	0.00789	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00781	0.00781	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—muscle cancer	0.00753	0.00753	CcSEcCtD
Fosamprenavir—Nervous system disorder—Vincristine—muscle cancer	0.00751	0.00751	CcSEcCtD
Fosamprenavir—Decreased appetite—Dactinomycin—muscle cancer	0.00745	0.00745	CcSEcCtD
Fosamprenavir—Fatigue—Dactinomycin—muscle cancer	0.00739	0.00739	CcSEcCtD
Fosamprenavir—Anorexia—Vincristine—muscle cancer	0.0073	0.0073	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00701	0.00701	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00698	0.00698	CcSEcCtD
Fosamprenavir—Abdominal pain—Dactinomycin—muscle cancer	0.00677	0.00677	CcSEcCtD
Fosamprenavir—Body temperature increased—Dactinomycin—muscle cancer	0.00677	0.00677	CcSEcCtD
Fosamprenavir—Decreased appetite—Vincristine—muscle cancer	0.00666	0.00666	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Vincristine—muscle cancer	0.00661	0.00661	CcSEcCtD
Fosamprenavir—Fatigue—Vincristine—muscle cancer	0.0066	0.0066	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00643	0.00643	CcSEcCtD
Fosamprenavir—Hypersensitivity—Dactinomycin—muscle cancer	0.00631	0.00631	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Vincristine—muscle cancer	0.00626	0.00626	CcSEcCtD
Fosamprenavir—Asthenia—Dactinomycin—muscle cancer	0.00615	0.00615	CcSEcCtD
Fosamprenavir—Neutropenia—Methotrexate—muscle cancer	0.00611	0.00611	CcSEcCtD
Fosamprenavir—Body temperature increased—Vincristine—muscle cancer	0.00605	0.00605	CcSEcCtD
Fosamprenavir—Abdominal pain—Vincristine—muscle cancer	0.00605	0.00605	CcSEcCtD
Fosamprenavir—Skin disorder—Etoposide—muscle cancer	0.00602	0.00602	CcSEcCtD
Fosamprenavir—Anorexia—Etoposide—muscle cancer	0.00591	0.00591	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.00589	0.00589	CcSEcCtD
Fosamprenavir—Diarrhoea—Dactinomycin—muscle cancer	0.00586	0.00586	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—muscle cancer	0.00579	0.00579	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00578	0.00578	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.00577	0.00577	CcSEcCtD
Fosamprenavir—Hypersensitivity—Vincristine—muscle cancer	0.00564	0.00564	CcSEcCtD
Fosamprenavir—Asthenia—Vincristine—muscle cancer	0.00549	0.00549	CcSEcCtD
Fosamprenavir—Vomiting—Dactinomycin—muscle cancer	0.00545	0.00545	CcSEcCtD
Fosamprenavir—Rash—Dactinomycin—muscle cancer	0.0054	0.0054	CcSEcCtD
Fosamprenavir—Decreased appetite—Etoposide—muscle cancer	0.00539	0.00539	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Etoposide—muscle cancer	0.00535	0.00535	CcSEcCtD
Fosamprenavir—Fatigue—Etoposide—muscle cancer	0.00535	0.00535	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—muscle cancer	0.00529	0.00529	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—muscle cancer	0.00526	0.00526	CcSEcCtD
Fosamprenavir—Diarrhoea—Vincristine—muscle cancer	0.00524	0.00524	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—muscle cancer	0.00523	0.00523	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—muscle cancer	0.00516	0.00516	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—muscle cancer	0.00513	0.00513	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—muscle cancer	0.0051	0.0051	CcSEcCtD
Fosamprenavir—Nausea—Dactinomycin—muscle cancer	0.00509	0.00509	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Etoposide—muscle cancer	0.00507	0.00507	CcSEcCtD
Fosamprenavir—Dizziness—Vincristine—muscle cancer	0.00506	0.00506	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.005	0.005	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—muscle cancer	0.00494	0.00494	CcSEcCtD
Fosamprenavir—Abdominal pain—Etoposide—muscle cancer	0.0049	0.0049	CcSEcCtD
Fosamprenavir—Body temperature increased—Etoposide—muscle cancer	0.0049	0.0049	CcSEcCtD
Fosamprenavir—Vomiting—Vincristine—muscle cancer	0.00487	0.00487	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—muscle cancer	0.00485	0.00485	CcSEcCtD
Fosamprenavir—Rash—Vincristine—muscle cancer	0.00483	0.00483	CcSEcCtD
Fosamprenavir—Dermatitis—Vincristine—muscle cancer	0.00482	0.00482	CcSEcCtD
Fosamprenavir—Headache—Vincristine—muscle cancer	0.0048	0.0048	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—muscle cancer	0.00472	0.00472	CcSEcCtD
Fosamprenavir—Hypersensitivity—Etoposide—muscle cancer	0.00457	0.00457	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—muscle cancer	0.00455	0.00455	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—muscle cancer	0.00455	0.00455	CcSEcCtD
Fosamprenavir—Nausea—Vincristine—muscle cancer	0.00455	0.00455	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—muscle cancer	0.00453	0.00453	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—muscle cancer	0.00447	0.00447	CcSEcCtD
Fosamprenavir—Asthenia—Etoposide—muscle cancer	0.00445	0.00445	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—muscle cancer	0.00445	0.00445	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—muscle cancer	0.00444	0.00444	CcSEcCtD
Fosamprenavir—Pruritus—Etoposide—muscle cancer	0.00439	0.00439	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—muscle cancer	0.00428	0.00428	CcSEcCtD
Fosamprenavir—Diarrhoea—Etoposide—muscle cancer	0.00424	0.00424	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—muscle cancer	0.0042	0.0042	CcSEcCtD
Fosamprenavir—Dizziness—Etoposide—muscle cancer	0.0041	0.0041	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—muscle cancer	0.00409	0.00409	CcSEcCtD
Fosamprenavir—Vomiting—Etoposide—muscle cancer	0.00394	0.00394	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—muscle cancer	0.00394	0.00394	CcSEcCtD
Fosamprenavir—Rash—Etoposide—muscle cancer	0.00391	0.00391	CcSEcCtD
Fosamprenavir—Dermatitis—Etoposide—muscle cancer	0.00391	0.00391	CcSEcCtD
Fosamprenavir—Headache—Etoposide—muscle cancer	0.00389	0.00389	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—muscle cancer	0.00388	0.00388	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—muscle cancer	0.00388	0.00388	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00385	0.00385	CcSEcCtD
Fosamprenavir—Nausea—Etoposide—muscle cancer	0.00368	0.00368	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—muscle cancer	0.00364	0.00364	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—muscle cancer	0.00361	0.00361	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—muscle cancer	0.00354	0.00354	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00338	0.00338	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—muscle cancer	0.00336	0.00336	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00333	0.00333	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—muscle cancer	0.00323	0.00323	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00321	0.00321	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—muscle cancer	0.0032	0.0032	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—muscle cancer	0.00312	0.00312	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—muscle cancer	0.00307	0.00307	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—muscle cancer	0.00304	0.00304	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—muscle cancer	0.0028	0.0028	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00278	0.00278	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—muscle cancer	0.00277	0.00277	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—muscle cancer	0.00274	0.00274	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—muscle cancer	0.00267	0.00267	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00263	0.00263	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—muscle cancer	0.00263	0.00263	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—muscle cancer	0.00254	0.00254	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—muscle cancer	0.00246	0.00246	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—muscle cancer	0.00236	0.00236	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—muscle cancer	0.00234	0.00234	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—muscle cancer	0.00234	0.00234	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—muscle cancer	0.00233	0.00233	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—muscle cancer	0.00231	0.00231	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—muscle cancer	0.00228	0.00228	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—muscle cancer	0.00213	0.00213	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—muscle cancer	0.00203	0.00203	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—muscle cancer	0.00202	0.00202	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—muscle cancer	0.00191	0.00191	CcSEcCtD
